IGFBP5 and diabetes mellitus: Eight weeks after diabetes induction, mice were divided into four groups: a nondiabetic control group and three STZ‐induced diabetic mice groups, which were administered intracavernous injections of phosphate buffered saline, scrambled control shRNA, or shRNA targeting mouse IGFBP5 (shIGFBP5) lentivirus particles.